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Abstract
Background: Few direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic
peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX),
pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the
efficacy and tolerability of DLX with PGB and GBP in DPNP, using placebo as a common comparator.
Methods: We searched PubMed, EMBASE, CENTRAL databases and regulatory websites for randomized, double-blind,
placebo-controlled, parallel group or crossover clinical trials (RCTs) assessing DLX, PGB, GBP and AMT in DPNP. Study
arms using approved dosages with assessments after 5–13 weeks were eligible. Efficacy criteria were: reduction in 24-
hour pain severity (24 h PS) for all three drugs, and response rate (≥ 50% pain reduction) and Patient Global Impression
of Improvement/Change (PGI-I/C) for DLX and PGB only. Tolerability criteria included: discontinuation, diarrhoea,
dizziness, headache, nausea and somnolence. Direct comparisons versus placebo were conducted with pooled fixed –
and random-effects analyses on endpoints reported in at least two studies of each drug. Indirect comparisons were
performed between DLX and each of PGB and GBP using Bayesian simulation.
Results: Three studies of DLX, six of PGB, two of GBP and none of AMT met the inclusion criteria. In random-effects
and fixed-effects analyses of DLX, PGB and GBP, all were superior to placebo for all efficacy parameters, with some
tolerability trade-offs. Indirect comparison of DLX with PGB found no differences in 24 h PS, but significant differences
in PGI-I/C, favouring PGB, and in dizziness, favouring DLX were apparent. Comparing DLX and GBP, there were no
statistically significant differences.
Conclusion: From the few available studies suitable for indirect comparison, DLX shows comparable efficacy and
tolerability to GBP and PGB in DPNP. Duloxetine provides an important treatment option for this disabling condition.
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Background
Neuropathic pain is often associated with diabetic periph-
eral neuropathy and is defined as pain initiated or caused
by a primary lesion or dysfunction in the nervous system
[1]. In a recent cross-sectional study in the UK, the overall
prevalence of chronic (>1 year) painful peripheral neu-
ropathy was estimated to be 16.2% among patients with
diabetes compared with 4.9% among matched controls
[2]. The rising prevalence of type 2 diabetes is likely to
increase the burden of diabetic peripheral neuropathic
pain (DPNP) [3].
The main symptoms of DPNP are burning or shooting
pain in the lower limbs and feet, usually occurring for
more than three months. Currently, there are no approved
treatments that restore nerve function. A major goal of
pharmacological treatment in DPNP is therefore to con-
trol pain. Simple analgesics may provide partial, short-
term relief, but more specifically targeted drugs are nor-
mally required for sustained control of pain of neuro-
pathic origin.
Amitriptyline, a tricyclic antidepressant (TCA) first mar-
keted in the 1960s, is not licensed for treatment of DPNP.
However, along with another TCA (nortriptyline), it is rec-
ommended in the British National Formulary as a drug of
choice for treating DPNP. More recently, the use of anticon-
vulsants has been proposed for the treatment of neuro-
pathic pain. Gabapentin is licensed for the treatment of
neuropathic pain in Europe and for the treatment of post-
herpetic neuralgia, a specific type of neuropathic pain, in
the US. Pregabalin was approved in 2004 for the treatment
of peripheral neuropathic pain in Europe, and in 2005 for
the treatment of neuropathic pain associated with diabetic
peripheral neuropathy and postherpetic neuralgia (PHN)
in the US. Duloxetine is a relatively balanced and potent
reuptake inhibitor of serotonin and norepinephrine,
approved in Europe and the US for the treatment of DPNP.
It was first approved as an antidepressant for the treatment
of major depressive disorder (MDD).
The aims of the meta-analysis were twofold. The first was to
summarize the efficacy and tolerability of drug treatments
licensed or recommended for DPNP by statistically pooling
the available data from randomized, placebo-controlled
trials. The second aim was to compare the efficacy and tol-
erability of duloxetine with pregabalin, gabapentin and
amitriptyline. As most of the controlled clinical trials of
these drugs are comparisons with placebo and very few
head-to-head comparisons exist, an indirect approach was
chosen using placebo as a common comparator.
Methods
Sources
A comprehensive and systematic search of the published
literature for trials of duloxetine (DLX), pregabalin (PGB),
gabapentin (GBP) and amitriptyline (AMT) in the treat-
ment of DPNP was performed during January 2005 using
PubMed, EMBASE and CENTRAL databases. The search
strategy was not limited by year or language of publica-
tion. Internal study reports of all trials of duloxetine in the
treatment of DPNP were provided by the primary study
sponsor, Eli Lilly and Company. We are not aware of any
trials of duloxetine conducted since the date of search. In
addition, the Food and Drug Administration (FDA) and
European Medicines Agency (EMEA) websites were
searched for available reviews of PGB and GBP. As PGB
had only recently been licensed for DPNP, it was consid-
ered that all trials completed by the manufacturer would
be identified through these websites.
Study selection and validity assessment
The drugs considered for inclusion in the meta-analysis
were those licensed (DLX, PGB, GBP) or recommended
(AMT) for DPNP, subject to a minimum requirement for
two eligible studies of any drug. Identified references were
screened using title, abstract and keywords. Studies were
considered potentially eligible for inclusion in the meta-
analyses of each individual drug if they were randomised,
double-blind, placebo-controlled trials in diabetic neu-
ropathy or diabetic peripheral neuropathic pain with a
treatment duration of 5–13 weeks, or longer provided that
results were reported for this duration. Studies could be of
parallel group or crossover design, but crossover studies
had to demonstrate sufficient washout period, randomi-
sation of the order of study treatment and that subjects
had stable disease over the study period. Evidence of sam-
ple size calculations for the primary efficacy variable was
required, consistent with CONSORT recommendations
for the reporting of clinical trials, as adopted by BioMed
Central[4] and other journals. Eligibility was confirmed
on review of full publications and/or study reports against
the above criteria.
Data abstraction
Study design data including design synopsis, treatment
comparators, dosage, titration schedule and duration of
treatment were abstracted, along with baseline character-
istics including summary statistics of pain severity, age
and sex. Summary efficacy and tolerability outcomes were
also abstracted. Data were entered into spreadsheets by
one author (ML) and were verified by another (SQ).
Selection of outcome measures
By assessing the commonality of outcome measures avail-
able across drugs and across the eligible studies of each
drug, a set of outcomes was identified for which sufficient
data were available for pooling, notwithstanding minor
differences in reporting.
The primary assessment of treatment efficacy, available
for all drugs, was 24-hour average pain severity (24 h PS),BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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treatment response and overall health improvement. 24 h
PS was recorded by patients in daily or weekly diaries on
an 11-point ordinal scale, ranging from 0 = no pain to 10
= worst pain possible. Treatment efficacy outcomes only
partially available were treatment response and patient
global impression. Treatment response was defined as at
least a 50% reduction in 24 h PS score from baseline, and
was reported as proportions of responders. The overall
health improvement was measured on the Patient Global
Impression of Improvement/Change (PGI-I/C) question-
naire, a 7-point ordinal, categorical scale describing
patients' reported impressions ranging from "very much
improved" to "very much worse" [5].
The most frequently reported tolerability outcomes were
considered. These included premature discontinuation
due to lack of efficacy and due to adverse events (AEs), as
well as the AE symptoms reported most frequently (>5%)
in patients receiving DLX and corresponding with those
reported in the studies of PGB and GBP: diarrhoea, dizzi-
ness, headache, somnolence and nausea. By definition,
only symptoms reported in common between drugs could
be included in the indirect meta-analyses. Treatment
effects for continuous variables, such as 24 h PS, were esti-
mated as the absolute difference between the mean
change from baseline to study endpoint. Treatment effects
for discrete variables (PGI-I/C, response rates and AE inci-
dence rates) were estimated as log-odds ratios.
To test for the significance of between-study differences,
analysis of variance (ANOVA) tests were used for continu-
ous baseline measures (age, treatment effect) and the
Cochrane-Mantel-Haentzel test was used for sex.
Quantitative data synthesis
Direct meta-analyses were performed to estimate effect
sizes for each drug compared to placebo, using classical
frequentist fixed-effects (FE) and random-effects (RE)
models. Studies were pooled by weighting the treatment
differences by their inverse variances. Comparisons
between drug and placebo were expressed as mean differ-
ences (θ) with 95% confidence intervals. Treatment differ-
ences between studies were tested using the Mann-
Whitney U-test. FE and RE models were estimated and
Cochrane Q-tests, I-squared and τ2 statistics were used to
test for and quantify between-study heterogeneity. Forest
plots were generated to assess the extent of this visually.
Superiority tests were performed for the direct compari-
sons of each active drug with placebo for each outcome,
using a one-sided 95% confidence interval (CI). The
number needed to treat (NNT) – the number of patients
that need to be treated with drug compared to placebo to
obtain one additional responder – and the number
needed to harm (NNH) for discontinuation due to AEs
were calculated. When 95% CIs for NNTs and NNHs were
not significant (e.g. if they included a negative CI bound)
the sign ∞ was used for the undefined bound [6]. The
NNTs/NNHs were derived from the estimated treatment
differences (θ) and from event probabilities in the control
group [7].
Due to the absence of head-to-head trials, the compari-
sons of DLX with the other active treatments were made
by means of indirect meta-analyses, using placebo as a
common comparator. These were performed using a Baye-
sian simulation approach. The adjusted outcomes of
active treatments vs. placebo from the direct comparison
were pooled across available studies, to derive estimates
of δ, the mean difference in treatment effect between DLX
and each comparator, along with 95% credibility inter-
vals. Non-informative prior distributions of θ  and the
between-study heterogeneity (τ2) were used.
Non-inferiority tests were performed for the comparisons
of 24 h PS between DLX and the other drugs. A difference
of 2 points on the 11-point scale was selected as the non-
inferiority margin, based on previous research into the
correspondence of 24 h PS scores with "very much
improved " and "much improved" ratings on the PGI
scale [8]. For the remaining outcomes, for which no con-
sensus exists on the minimum clinically meaningful dif-
ference, superiority tests were performed.
Results
Literature search
Figure 1 presents the results of the literature search,
screening and review for those studies deemed eligible for
inclusion in the meta-analysis. From 91 potentially rele-
vant publications, 11 were included in the meta-analysis.
Of the four randomized studies of AMT potentially eligi-
ble, one had a very small sample (n = 25) with no sample
size calculation and was, therefore, excluded[9] Two stud-
ies included benzotropine as an active placebo (to pre-
serve blinding by mimicking the anticholinergic side-
effects of amitriptyline). This precluded any tolerability
comparison with no treatment. Of these two studies, one
was a crossover study with no washout period. In the
other, AMT was not directly compared to placebo. The
sole remaining eligible study involving AMT was one of
the studies of PGB (DPN-040), which included AMT as a
control in addition to placebo. Due to the pre-specified
minimum requirement for two eligible studies of any
drug, AMT was eliminated from the meta-analysis. Hence,
the meta-analysis included DLX (three unpublished stud-
ies at the time of searching, available as manufacturer's
study reports)[10,11], GBP (two published stud-
ies)[12,13] and PGB (six studies, comprising four unpub-
lished at the time of searching, available as EMEA
Scientific Discussions, and two published studies) [14-
16]. The three DLX studies included 679 patients on activeBMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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treatment and 339 on placebo; the GBP studies included
114 patients on active treatment and 111 on placebo and
the PGB studies included 988 patients on active treatment
and 478 on placebo.
For the DLX vs. PGB comparison, three efficacy outcomes
were considered: 24 h PS, pain response and PGI-I/PGI-C,
and seven tolerability outcomes: premature discontinua-
tion due to adverse events, due to lack of efficacy and due
to other reasons, dizziness, somnolence, headache and
diarrhoea. For the DLX vs. GBP comparison, only the 24
h PS efficacy comparison was possible due to lack of GBP
data. However, all eight tolerability outcomes were possi-
ble, comprising the seven described above plus nausea.
Some outcome measures were excluded as they were
reported for some but not all of the drugs, or for some but
not all trials of a drug. The three studies of DLX included
some efficacy outcomes not present in the other drug
studies. These included the night pain severity, the Brief
Pain Index (BPI), the Clinical Global Impression of Sever-
ity (CGI-S), all of which were absent from studies of the
other drugs, and the Short Form McGill Pain Question-
naire (SF-MPQ), which was included in two of the six PGB
studies and one of the two GBP trials. Because it is an anti-
depressant, the studies of DLX in DPNP excluded patients
with diagnosed depression to avoid biasing estimates of
the direct effect of DLX on DPNP. This restriction did not
apply to GBP and PGB.
Study characteristics
Table 1 illustrates the design and baseline characteristics
of the studies included in the meta-analyses. The treat-
ment duration varied between 5 and 12 weeks and the
study dosage of individual drugs varied. Only study arms
using therapeutic dosage corresponding to regulatory
labelling were eligible for inclusion. In testing for overall
between-study heterogeneity, significant differences were
detected in the proportions of patients by sex (p < 0.0001)
and by co-morbid type 2 diabetes (p < 0.0001), while no
significant differences were found in baseline pain sever-
ity or age.
Meta-analysis
Direct comparison results
As heterogeneity between studies measured by the Q-test
was not significant and the FE and RE models produced
similar estimates of treatment effect for the primary and
the other outcomes, only the results from the random-
effects models are reported here.
All three drugs were superior to placebo for all efficacy
parameters. (Please note: effects (θ) favouring drug over
placebo take a negative sign for the outcome measures 24
h PS, PGI-I/C and tolerability but a positive sign for
response). For 24 h PS, θ (95% CIs) were DLX: -1.13 (-
1.36; -0.89), PGB: -0.90 (-1.23; -0.57), GBP: -1.44 (-2.21;
-0.66). Corresponding θ  values for response rate were
DLX: 0.86 (0.63; 1.09) with NNT of 5 (3; 7), PGB: 0.84
(0.52; 1.16) with NNT of 5 (4; 8); and for PGI-I/C were
DLX: -0.76 (-1.00; -0.51), PGB: -1.29 (-1.72; -0.86).
The forest plots in Figure 2 show point estimates and 95%
CIs for the primary efficacy outcome, 24 h PS, for individ-
ual trials of each drug, along with pooled FE and RE esti-
mates and I-squared statistics.
Table 2 presents the results of the RE analyses of DLX vs.
placebo. DLX was statistically significantly more effective
than placebo on all three efficacy variables. The U-test was
statistically significant (indicating the existence of treat-
ment effects) for all efficacy outcomes and all tolerability
outcomes except discontinuation due to other reason and
diarrhoea. DLX resulted in significantly lower premature
discontinuation due to lack of efficacy than placebo. Pre-
mature discontinuation due to adverse events was signifi-
Flow diagram of systematic review to identify eligible studies Figure 1
Flow diagram of systematic review to identify eligible 
studies.
Potentially relevant studies 
identified and screened 
(n=91) 
Studies excluded (n=55): 
General reviews of the drugs, general reviews 
of the disease area, studies of other drugs in 
the treatment of DPNP, studies of other 
disease areas, one study concerned with the 
importance on the Likert scale in DPNP and 
PHN, non placebo-controlled studies 
Studies potentially eligible 
after screening( n=36)
Studies excluded (n=19) due to 
duplicates from different database 
searches  
Studies reviewed in full 
(n=17)
Studies excluded (n=6). 
Gabapentin (n=2). 
Backonja (1999): repeat publication of 
Backonja (1998) 
Gorson (1999): brief report of cross-over trial, 
apparently inadequate washout 
Amitriptyline (n=4). 
Mendel (1986) studied combination therapy 
Max (1987 and 1992): used active placebo 
Vrethem (1997) n=25: no sample size 
calculation
Studies eligible for 
inclusion in the meta-
analysis (n=11): 
Duloxetine = 3 
Pregabalin = 6 
Gabapentin = 2 
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Table 1: Study design and patient baseline characteristics.*
Study Druga Dose Titration Randomised
patients (N)
Treatment
duration 
(weeks)
Baseline severity
(24-hour
pain intensity
score) Mean (sd)
Diabetes
type
(% Type 2)
Diabetes
Duration
(years)
Mean (sd)
Diabetes
Duration
(years)
Median
DPNP
Duration
(years)
Mean
Age
(years)
Mean
(sd)
Gender 
(% male)
Duloxetine
HMAW Duloxetine 60 mg QD 112 12 6.01
(1.69)
87.7 11.42
(8.20)
9.87 3.81 59.21
(11.61)
69.3
Duloxetine 60 mg BID 3 days 109 5.85
(1.38)
90.3 10.06
(8.95)
7.49 3.45 60.5
(10.84)
60.2
Placebo 115 5.73
(1.52)
90.4 11.44
(11.26)
7.52 4.03 60.42
(10.5)
51.3
HMAVa Duloxetine 60 mg QD 114 12 6.12
(1.62)
91.2 9.74
(9.55)
6.35 3.59 59.71
(11.17)
64.9
Duloxetine 60 mg BID 3 days 112 6.21
(1.54)
92 9.88
(10.01)
6.65 4.38 61.46
(9.94)
54.5
Placebo 108 5.85
(1.42)
89.8 11.08
(9.09)
9.11 3.53 60.81
(10.57)
63.9
HMAVb Duloxetine 60 mg QD 116 12 5.55
(1.12)
80.2 14.64
(8.92)
14.06 4.52 58.29
(10.88)
41.4
Duloxetine 60 mg BID 3 days 116 5.65
(1.29)
85.3 13.93
(9.72)
11.35 4.47 58.98
(9.58)
52.6
Placebo 116 5.47
(1.25)
87.9 12.83
(8.64)
11.32 3.98 59.2
(9.84)
45.7
Pregabalin
DPN-029 Pregabalin 100 mg 
TID
1 wk 82 5 6.2
(1.4)
93.8 7 59
(9.2)
59.3
Pregabalin 200 mg 
TID
1 wk 82 6.2
(1.5)
92.7 6.5 62
(9.7)
63.4
Placebo 1 wk 97 6.6
(1.5)
85.6 8 57.8
(11.6)
60.8
DPN-131 Pregabalin 100 mg 
TID
76 8 6.5 84.2 9.4
(10.3)
65 9 . 2
(12.3)
55.3
Placebo 70 6.1 90 9.3
(10.5)
5.5 60.3
(10.3)
57.1
DPN-014 Pregabalin 50 mg TID 2 wks 79 6 6.5 91.1 4 56.3
(9.4)
Pregabalin 200 mg 
TID
2 wks 82 6.7 97.6 6.5 57.8
(9.5)
Placebo 2 wks 85 6.9 83.5 9 57.1
(10.3)B
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DPN-040 Pregabalin 200 mg 
TID
2 wks 87 8 6.9 87.2 10.5 62
(9.4)
Amitriptylin
e
25 mg TID 2 wks 88 6.4 82.8 9 57.8
(12.0)
Placebo 2 wks 81 6.3 87.7 11 60.6
(11.5)
DPN-149 Pregabalin 75 mg BID 1 wks 99 12 6.2 86 12 58.5
(12.6)
Pregabalin 150 mg 
BID
1 wks 99 6.4 84 12.5 57.6
(10.5)
Pregabalin 150/300 mg 
BID
1 wk 101 6.6 86 11 59.5
(11.4)
Placebo 1 wk 97 6.4 86 11 58.8
(11.8)
DPN-155 Pregabalin 600 mg 
QID
1 wk 96 8 6.67 82.3 13.2 11.4 61.8
(11)
54.5
Pregabalin Flexible 
dose
150 – 600 
mg
1 wk 105 6.67 84.8 13.8 10.4 62.7
(10.6)
52.5
Placebo 48 6.55 81.3 13.6 11.5 61.7
(12.6)
56.9
Gabapentin
Backonja
1998
Gabapentin 1200 mg 
TID
4 wks 84 8 6.4 75 12
(9.6)
53
(10.5)
58.3
Placebo 4 wks 81 6.5 75 11.2
(8.7)
53
(10.5)
61.7
Simpson
2001
Gabapentin 1200 mg 
TID
4 wks 30 8 6.4 80 8
(7.4)
48
(8.2)
60
Placebo 4 wks 30 6.5 83 9
(7.8)
52
(9.8)
60
*Note: duloxetine trial arms with dose 20 mg QD and pregabalin trial arms with dose 25 mg TID were excluded from the meta-analysis;
aQD: Once daily; BID: Twice daily; TID: Three times daily.
Table 1: Study design and patient baseline characteristics.* (Continued)BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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cantly more common for DLX than for placebo (NNH =
11 (95% CI: 7; 23)). Between-study variance (τ2 ≠ 0) was
detected for only two of the individual adverse event out-
comes (diarrhoea and nausea). For the individual tolera-
bility outcomes, DLX gave rise to a significantly higher
incidence of dizziness, headache, nausea and somnolence
than did placebo.
Table 3 presents the results of the RE analyses of PGB vs.
placebo. As for DLX, PGB was significantly more effective
than placebo on all three efficacy variables. A significantly
lower rate of premature discontinuation due to lack of
efficacy was seen for PGB than for placebo. Premature dis-
continuation due to AEs occurred significantly more fre-
quently for PGB than for placebo (NNH = 19 (95% CI: 10;
48)). Heterogeneity between PGB studies was observed
for all efficacy variables and for diarrhoea and dizziness.
PGB gave rise to a significantly higher incidence of dizzi-
ness and somnolence than did placebo.
Table 4 presents the results of the RE model for GBP vs.
placebo. GBP was significantly superior to placebo for
reduction in 24 h PS, the only efficacy outcome available
in common for DLX and GBP. It was not possible to cal-
culate an NNT for GBP, as binary responder rate data were
unavailable. The incidence of dizziness and of somno-
lence was significantly greater for GBP than for placebo.
For the remaining tolerability outcomes, no significant
differences were found between GBP and placebo.
Indirect comparison results
The results of the indirect comparisons between DLX and
PGB are presented in Table 5. For the primary efficacy out-
come, reduction in 24 h PS, a difference of -0.248 (95%
CI: -0.667; 0.162) was seen in favour of DLX. Hence, DLX
was not inferior to PGB on this outcome, as the upper
bound of the confidence interval did not exceed the non-
inferiority margin of +2 points. For response, the differ-
ence between DLX and PGB was close to zero and not sig-
nificant. For the patient global impression (PGI-I/PGI-C)
outcomes, PGB showed an improvement of 0.542 points
over DLX, a difference that just reached significance (95%
CI: 0.016; 1.060). DLX produced a significantly lower
incidence of dizziness than did PGB, with δ = -1.084 (-
1.903; -0.317). In the other tolerability comparisons (pre-
mature discontinuation, diarrhoea, headache, somno-
lence), no statistically significant differences were found.
Table 6 presents the results from the indirect adjusted
meta-analysis of DLX vs. GBP, in which no statistically sig-
nificant differences were found.
Discussion
This meta-analysis set out to compare the efficacy and tol-
erability of duloxetine, which is approved for the treat-
ment of DPNP, with other drugs licensed or
recommended in this indication. A variety of drugs, prin-
cipally antidepressants, anticonvulsants and opioid anal-
gesics, have been proposed for use in this difficult-to-treat
condition. For example, controlled-release oxycodone has
shown efficacy in diabetic painful neuropathy in two
small trials [17,18]. However, at present the only formally
licensed agents for DPNP are duloxetine, gabapentin and
pregabalin, while amitriptyline is unlicensed but recom-
mended for DPNP. The intended comparators to duloxet-
ine in this study were, therefore, the tricyclic
antidepressant amitriptyline and the γ-aminobutyric acid
(GABA) analogues gabapentin and pregabalin.
Our approach to selecting efficacy outcomes for pooling
was stricter than some previous meta-analyses in neuro-
pathic pain. A common metric for 24 h PS based on an 11-
point ordinal scale was used in the trials of duloxetine,
gabapentin and pregabalin in DPNP. This allowed us to
use this outcome directly and to construct from it a meas-
ure of responder rate (proportion of patients achieving
50% pain reduction). In reviews of unlicensed drugs and
neuropathic pain more generally, the lack of standardisa-
tion of outcome measures across trials has required a
looser definition of response rate. Previous reviews [19-
21] have reported NNTs based on the criterion of 50%
pain reduction, but NNTs have also been derived from
various pain scales or approximations made where data
were not available. For consistency, we have reported sim-
ilarly-derived NNT (and NNH) values for the placebo
comparisons.
DLX was statistically superior to placebo for all three effi-
cacy outcomes and for premature discontinuation due to
lack of efficacy. Duloxetine gave rise to significantly
greater incidences of dizziness, headache, nausea, somno-
lence and premature discontinuation due to adverse
events. A similar pattern was seen with PGB, which was
statistically superior to placebo for the three efficacy out-
comes and for premature discontinuation due to lack of
efficacy. PGB produced a significantly greater incidence of
somnolence, dizziness and premature discontinuation
due to adverse events. GBP was significantly superior to
placebo in reducing 24 h PS and produced significantly
greater scores for dizziness and somnolence than did pla-
cebo.
Our estimated NNT of 5 (95% CI: 3; 7) for the pooled
studies of DLX compares with the NNTs reported else-
where of 5.2 (95% CI: 3.7; 8.5) [22] and 4.1 (95% CI: 2.9;
7.2) [20], the latter estimate based on the first published
trial of DLX [23]. Our estimated NNT for PGB (5 (95% CI:
4; 8)) was slightly higher than a previously reported value
(4.2 (95% CI: 3.4; 5.4)) [24], due to our inclusion of stud-
ies DPN-149 and DPN-040. The NNTs for the individual
PGB studies were very similar to those provided in a recent
review [25]. Data on GBP were limited and did not pro-BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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Forest plots: change in average 24-hour pain score, direct comparisons with placebo Figure 2
Forest plots: change in average 24-hour pain score, direct comparisons with placebo.
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Table 2: Random-effects pooled results: duloxetine vs. placebo.
Outcome Treatment effect (θ) 95% CI for θ U-test
(p-value)
τ2 NNT/NNH
(95% CI)
Efficacy
Reduction in 24-hour pain intensity -1.128 (-1.364; -0.891) <0.001 0 -
Response 0.856 (0.628; 1.085) <0.001 0 5(3;7)
PGI -0.756 (-1.004; -0.508) <0.001 0 -
Tolerability
Premature study discontinuation due to:
- Lack of efficacy -0.962 (-1.800; -0.124) (0.024) 0
- Adverse events 1.077 (0.663; 1.490) <0.001 0 11 (7; 23)
- Other -0.278 (-0.636; 0.079) (0.127) 0
Diarrhoea 0.233 (-0.436; 0.903) (0.307) 0.307
Dizziness 0.817 (0.398; 1.235) <0.001 0
Headache 0.468 (0.090; 0.845) (0.015) 0
Nausea 1.306 (0.942; 1.669) 0.039 0.039
Somnolence 1.472 (1.044; 1.900) <0.001 0
Note:
θ is absolute difference for 24-hour pain intensity.
θ is log-odds ratio for Response, PGI and all tolerability analyses.
τ2 is between-study heterogeneity.
NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for 
discontinuation due to adverse events.
Table 3: Random-effects pooled results: pregabalin vs. placebo.
Outcome Treatment effect (θ) 95% CI for θ U-test
(p-value)
τ2 NNT/NNH
(95% CI)
Efficacy
Reduction in 24-hour pain intensity -0.901 (-1.234; -0.568) <0.001 0.147
Response 0.840 (0. 524; 1.155) <0.001 0.154 5(4;8)
PGI -1.291 (-1.722; -0.860) <0.001 0.019
Tolerability
Premature study discontinuation due to:
- Lack of efficacy 0.713 (-1.205; -0.221) (0.005) 0
- Adverse events 0.926 (0.463; 1.389) <0.001 0 19 (10; 48)
- Other -0.209 (-0.721; 0.302) (0.330) 0
Diarrhoea -0.660 (-1.734; 0.414) 0.139 0.139
Dizziness 1.900 (1.314; 2.487) 0.028 0.028
Headache -0.216 (-0.823; 0.392) 0.486 0
Somnolence 2.063 (1.361; 2.764) <0.001 0
Note:
θ is absolute difference for 24-hour pain intensity.
θ is log-odds ratio for Response, PGI and all tolerability analyses.
τ2 is between-study heterogeneity.
NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for 
discontinuation due to adverse events.BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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vide information on treatment response. Recent reviews
reported NNTs of 3.4 (95% CI: 2.1; 5.4) or 3.8 (95% CI:
3.4; 5.4) in DPNP for GBP [24,26]. Otherwise, previous
meta-analyses in neuropathic pain differ from the present
study in indications and drugs studied, so are not directly
comparable. Two reviews [20,26] concluded that across
the neuropathic conditions relieved by these agents, the
tricyclic antidepressants (TCAs) appear to have the lowest
NNT, at approximately 3, though as noted in the recent
EFNS guidelines [22] the individual trials are invariably
small, crossover studies that may overestimate the efficacy
of TCAs.
Table 4: Random-effects pooled results: gabapentin vs. placebo.
Outcome Treatment effect (θ) 95% CI for θ U-test
(p-value)
τ2 NNT/NNH
(95% CI)
Efficacy
Reduction in 24-hour pain intensity -1.437 (-2.211; -0.663) <0.001 0.109 *
Tolerability
Premature study discontinuation due to:
- Lack of efficacy -1.066 (-2.786; 0.653) 0.224 0
- Adverse events 0.241 (-0.786; 1.267) 0.646 0 63 (30; ∞)
- Other -0.036 (-1.162; 1.090) 0.950 0
Diarrhoea 0.393 (-0.555; 1.341) 0.416 0
Dizziness 1.833 (0.834; 2.833) <0.001 0
Headache 1.146 (-0.018; 2.310) 0.054 0
Nausea 0.595 (-0.532; 1.722) 0.301 0
Somnolence 1.582 (0.643; 2.520) 0.001 0
Note:
θ is absolute difference for 24-hour pain intensity.
θ is log-odds ratio for all tolerability analyses.
τ2 is between-study heterogeneity.
NNT/NNH: Number needed to treat, number needed to harm. * NNT was not calculated, due to absence of required binary data on responder 
rates. NNH was calculated for discontinuation due to adverse events.
Table 5: Indirect comparison results: duloxetine vs. pregabalin.
Outcome Indirect treatment comparison 
(δ)
Mean (median)
95% CI for δ Between-study variance 
(τ 2)
Mean (median)
95% CI for 
τ2
Efficacy
Reduction in 24-hour pain intensity -0.248 (0.248) (-0.667;0.162) 0.052 (0.024) (0.001;0.252)
Response 0.033 (0.034) (-0.393;0.451) 0.075 (0.052) (0.001;0.287)
PGI-I/PGI-C 0.542 (0.545) (0.016;1.060) 0.025 (0.009) (0.001;0.151)
Tolerability
Premature study discontinuation due 
to:
- Lack of efficacy -0.251 (-0.235) (-1.288;0.717) 0.058 0.015) (0.001;0.381)
- Adverse events 0.152 (0.154) (-0.505;0.790) 0.039 (0.012) (0.001;0.243)
- Other -0.068 (-0.069) (-0.735;0.589) 0.045 (0.013) (0.001;0.281)
Diarrhoea 0.886 (0.885) (-0.414; 2.183) 0.248 (0.050) (0.001; 1.628)
Dizziness -1.084 (-1.074) (-1.903; -0.317) 0.075 (0.020) (0.001; 0.477)
Headache 0.700 (0.704) (-0.078; 1.458) 0.037 (0.011) (0.001; 0.235)
Somnolence -0.554 (-0.552) (-1.458; 0.328) 0.052 (0.013) (0.001; 0.347)
Note:
δ is the mean difference in treatment effect between DLX and each comparator.
τ2 is between-study heterogeneity.BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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Indirect adjusted comparisons were performed between
DLX and PGB and between DLX and GBP, using placebo
as the common comparator. Comparing DLX with PGB,
only two comparisons reached significance: PGI-I/PGI-C,
which favoured PGB, and the incidence of dizziness,
which favoured DLX. In the comparisons between DLX
and GBP, no statistically significant differences were
detected.
Meta-analysis can be a powerful tool for comparing treat-
ments across individual clinical trials, but caution is
needed in its application and in the interpretation of
results. We comment below on some limitations of the
present study. The precision of the effect size estimated by
meta-analysis depends in part upon the number of con-
tributing trials and their size. Only in the last few years
have formal clinical programs to support regulatory
approval of drugs proposed for use in DPNP been carried
out. This is reflected in the small number of trials that met
the eligibility criteria for this meta-analysis.
In particular, the exclusion of amitriptyline from the
meta-analysis warrants discussion as, along with other
TCAs, it has been used in painful diabetic neuropathy for
approximately 30 years. Although strong consensus exists
for the clinical value of the TCAs, the clinical evidence
stems from a series of small trials mainly conducted in the
1980s and 1990s, which were not designed to meet cur-
rent regulatory requirements. As a result, relatively few
studies met the formal criteria for inclusion in this meta-
analysis. Among 20 articles describing the use of AMT in
neuropathic pain, four were clinical trials of AMT mono-
therapy but only one of these, in which AMT and PGB
were compared to placebo, met our pre-specified eligibil-
ity criteria. In that study, AMT achieved a numerically
greater response rate than PGB. Of the two studies by Max,
[27,28] the earlier was a small crossover study with no
washout period between AMT and placebo. The later
study randomised subjects to one of two crossover com-
parisons: AMT vs. desipramine and fluoxetine vs. placebo.
Twenty patients completed both comparisons but no
direct comparison of AMT and placebo was reported. The
studies by Max employed different pain measures from
those used in the DLX, GBP and PGB studies. Moreover,
benzotropine was used as an active placebo to mimic the
anticholinergic side-effects of amitriptyline. This was
designed to preserve blinding but precluded any tolerabil-
ity comparison between AMT and no treatment.
Nevertheless, systematic reviews have reported NNT/
NNH values for AMT and the TCAs as a class, based on
various definitions of response. For example, Finnerup
[20] reported a pooled NNT for the TCAs in peripheral
pain of 2.3 (95% CI 2.1–2.7). McQuay[21] reported an
NNT for AMT of 2.1 (95% CI 1.5–3.5), based on Max[28].
This was calculated from the 15 of 29 patients on AMT
and 1 of 29 on placebo who reported "complete", "virtu-
ally complete" or "a lot of" relief. McQuay reported an
NNT of 15.3 (95% CI 3.5–8) for fluoxetine, based on 22
of 46 patients on fluoxetine and 19 of 46 on placebo who
achieved "complete", "a lot of" or "moderate" relief stud-
ied by Max [27]. The only trial involving AMT using the
response rate criteria of our meta-analysis was the regula-
tory trial DPN-040 of pregabalin, which included AMT as
Table 6: Indirect comparison results: duloxetine vs. gabapentin.
Outcome Indirect treatment comparison 
(δ)
Mean (median)
95% CI for δ Between-study variance 
(τ 2)
Mean (median)
95% CI for 
τ2
Efficacy
Reduction in 24-hour pain intensity 0.270 (0.266) (-0.469; 1.022) 0.041 (0.013) (0.001; 0.247)
Tolerability
Premature study discontinuation due 
to:
- Lack of efficacy 0.067 (0.065) (-1.988; 2.116) 0.177 (0.028) (0.001; 1.281)
- Adverse events 0.841 (0.835) (-0.348; 2.065) 0.062 (0.015) (0.001; 0.406)
- Other -0.245 (-0.252) (-1.527; 1.075) 0.060 (0.015) (0.001; 0.386)
Diarrhoea -0.244 (-0.246) (-1.645; 1.164) 0.273 (0.051) (0.001; 1.825)
Dizziness -1.044 (-1.054) (-2.258; 0.183) 0.090 (0.021) (0.001; 0.590)
Headache -0.689 (-0.697) (-1.986; 0.638) 0.053 (0.013) (0.001; 0.348)
Nausea 0.704 (0.700) (-0.567; 2.021) 0.085 (0.022) (0.001; 0.529)
Somnolence -0.101 (-0.107) (-1.249; 1.078) 0.080 (0.016) (0.001; 0.545)
Note:
δ is the mean difference in treatment effect between DLX and each comparator.
τ2 is between-study heterogeneity.BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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an active control as well as placebo. The NNT for response
for AMT compared to placebo in this study was 5, rather
higher than reported elsewhere. Therefore, when compar-
ing NNT values across studies, it should be recognised that
these depend, inter alia, on the underlying definitions of
response. The accepted convention in pain studies is to
define the NNT as the number of patients needed to treat
to obtain one patient with at least 50% pain relief, but
obtaining this statistic may require some subjectivity. In
our meta-analysis, the outcome of 24 h PS measured on
an 11-point ordinal scale was available across all included
trials, so responder rates based on at least 50% pain relief
could be obtained in a consistent manner. In other stud-
ies, various categorical scales have been used and judge-
ment is required as to which levels of response correspond
to 50% or greater pain relief. While we acknowledge that
inclusion of AMT would have been desirable in view of
the consensus for its clinical value and its widespread use
in DPNP, the above data constraints precluded that possi-
bility for this particular study.
Although opioids were excluded from this meta-analysis,
as none is licensed in painful diabetic neuropathy, oxyco-
done has been shown to be effective in this indication in
two randomized, placebo-controlled trials [17,18]. Euro-
pean guidelines [22] report a combined NNT for these tri-
als of 2.6 (95% CI 1.9–4.1), though they warn that the
eligibility of prior opioid users may have exaggerated the
response rate.
Only two small studies of GBP were eligible. The three
studies of DLX and six studies of PGB involved more
patients, reflecting that these were trials designed to meet
regulatory authorities' requirements. Pooled estimates
from small numbers of trials may gain little in precision
over estimates from the individual trials. This is not nec-
essarily a concern where trials are large and adequately
powered, where differences in effect sizes are large, or
both. However, the two studies of GBP contributed only
114 patients on active drug, and pooling them produced
only modest shrinkage in the confidence intervals. More-
over, concerns have been expressed that small studies tend
to suffer from design shortcomings, such that they over-
estimate effect size [29]. It was not possible to calculate an
NNT for GBP. Therefore, we believe that the most impor-
tant and valid results in this study are the direct compari-
sons of DLX and PGB with placebo and the indirect
comparisons between DLX and PGB. Investigating the
validity of indirect adjusted comparisons, Song [30]
found that the results of indirect comparisons usually, but
not always, agree with results from head-to-head ran-
domised clinical trials, and concluded that in the absence
of direct evidence, adjusted indirect comparisons may
provide useful information.
The possibility of study selection bias is a potential threat
to the validity of meta-analyses. For DLX and PGB, we are
confident that all studies in DPNP were identified, and
that selection bias was therefore unlikely. As of the date
the literature search was performed, the manufacturer
provided study reports of all completed trials of DLX,
none of which had been published. The three eligible tri-
als of DLX have since been published [23,31,32]. No rele-
vant trials have been conducted since the time of the
search. We did not contact the manufacturer of PGB and
GBP to identify unpublished studies, as we considered
that all relevant evidence would have been disclosed to
the FDA and EMEA, whose drug assessments are in the
public domain. The European Public Assessment Report,
which was published in December 2004, only one month
prior to our literature search, stated that it included all six
completed trials of PGB in DPNP. Two of these six trials
had been published at the time of search[15,16], and a
further three [33-35] had been published as of October
2008. The apparently unpublished study is DPN-040,
which included AMT as an active comparator. All six stud-
ies we identified, along with a recently completed seventh
trial [36] not revealed by our search, have recently been
the subject of an article [37] reviewing dose response to
PGB. For GBP, which is a patent-expired drug, it is
unlikely that any recent (unpublished) manufacturer-
sponsored trials have been conducted.
The systematic review process to determine study eligibil-
ity appears to have resulted in a reasonably homogeneous
selection. Trial designs shared many common features,
outcome metrics and patient characteristics (except for
gender and proportion with type 2 diabetes), and we
detected little evidence of overall heterogeneity between
the trials included. With respect to the between-study var-
iability in outcomes for each drug, there were no signifi-
cant differences, but we conservatively chose to report RE
as well as FE models in the drug vs. placebo comparisons.
To demonstrate the equivalence of two drugs, it is com-
mon practice to perform tests of non-inferiority. In the
context of DPNP, 24 h PS is the only efficacy outcome for
which a clinically meaningful non-inferiority margin has
been documented, based on the work of Farrar [8], who
proposed a margin of two points on the 11-point pain
intensity rating scale. However, it was unnecessary to
invoke this non-inferiority margin in the comparisons of
DLX with PGB and GBP. Using the stricter criterion of
equivalence, there was no difference in the 24 h PS scores
between DLX and each of these comparator drugs, and we
conclude that DLX is equivalent to GBP and PGB on this
outcome. Although PGB showed a statistically greater
score than DLX on the PGI-I/PGI-C outcome, it is not
clear that the measured difference of approximately 0.5
points is clinically meaningful. This categorical seven-BMC Neurology 2009, 9:6 http://www.biomedcentral.com/1471-2377/9/6
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point scale describes "very much improved", "much
improved", "minimally improved", "no change", "mini-
mally worse", "much worse" and "very much worse".
Intuitively, it is difficult to conclude that less than a whole
interval change on this scale is meaningful. If a whole
interval were accepted as the non-inferiority margin, DLX
would be non-inferior to PGB in terms of patients' global
impressions.
The indirect comparisons of tolerability were, by defini-
tion, limited to those outcomes for which data were
reported in common for each comparator. One outcome
for which a comparison was not possible in this study was
weight gain. The European Public Assessment Report
refers to dose-related weight gain with PGB (2.4–8.2% of
patients), compared to 0.8% of placebo-treated patients,
over all neuropathic pain indications. Among DPNP
patients for whom data were available, the mean weight
gain over the assessment period was 1.6 kg for PGB-
treated patients and 0.3 kg for placebo-treated patients. In
the Integrated Safety Summary for DLX in diabetic neuro-
pathic pain, DLX did not differ significantly from routine
care or placebo controls in the incidence of weight gain.
Conclusion
Based on the pooling of common outcomes measured in
randomized, controlled trials, we conclude that duloxet-
ine is comparably effective and tolerable in the treatment
of diabetic peripheral neuropathic pain to two anticon-
vulsants, gabapentin and pregabalin, which are pharma-
cologically unrelated to duloxetine. The summary
reporting of trial results tends to conceal that response
and tolerability to the various types of pharmacological
treatment may be highly individual. In neuropathic pain,
the empirical approach to treatment and the common use
of off-label treatments attest to the clinical need for a wide
range of drug choices. This study suggests that duloxetine
may offer a valuable, additional option for this disabling
condition.
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